Natural Product (NP) Details
General Information of the NP (ID: NP0445) | |||||
---|---|---|---|---|---|
Name |
Cardamonin
|
||||
Synonyms |
CARDAMOMIN; Alpinetin chalcone; Dihydroxymethoxychalcone; 18956-16-6; 2',4'-dihydroxy-6'-methoxychalcone; UNII-H8KP1OJ8JX; 1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenylprop-2-en-1-one; 2-Propen-1-one, 1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenyl-, (2E)-; H8KP1OJ8JX; (E)-1-(2,4-Dihydroxy-6-methoxyphenyl)-3-phenyl-2-propen-1-one; CHEMBL378104; 2-Propen-1-one, 1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenyl-; (2E)-1-(2,4-Dihydroxy-6-methoxyphenyl)-3-phenyl-2-propen-1-one; (E)-1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenylprop-2-en-1-one; (E)-1-(2,4-Dihydroxy-6-methoxy-phenyl)-3-phenyl-propenone; Cardamoni; Cardamonin ,(S); 2'4'-Dihydroxy-6'-methoxy-chalcone; MLS000876992; SCHEMBL449220; MEGxp0_000534; Cardamonin, >=98% (HPLC); ACon1_000221; CHEBI:125601; HMS2271N04; HY-N0279; ZINC4716487; BDBM50185446; LMPK12120245; MFCD00238554; s3867; AKOS015896716; CCG-208127; DB14122; MCULE-6098713539; NCGC00180767-01; DS-15713; SMR000440601; B7085; CS-0008777; W1234; 309C149; A813330; J-012229; Q-100234; Q5038242; BRD-K61559475-001-01-0; 1-(2\\',4\\'-Dihydroxy-6\\'-methoxy-phenyl)-3-phenyl-propenone; (2E)-1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenylprop-2-en-1-one; (E)-1-(2,4-dihydroxy-6-methoxy-phenyl)-3-phenyl-prop-2-en-1-one; (E)-1-[2-methoxy-4,6-bis(oxidanyl)phenyl]-3-phenyl-prop-2-en-1-one; NCGC00180767-02!(E)-1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenylprop-2-en-1-one
Click to Show/Hide
|
||||
Species Origin | Alpinia zerumbet ... | Click to Show/Hide | |||
Alpinia zerumbet | |||||
Disease | Breast cancer [ICD-11: 2C60] | Investigative | [1] | ||
Structure |
Click to Download Mol2D MOL |
||||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C16H14O4
|
||||
PubChem CID | |||||
Canonical SMILES |
COC1=CC(=CC(=C1C(=O)C=CC2=CC=CC=C2)O)O
|
||||
InChI |
1S/C16H14O4/c1-20-15-10-12(17)9-14(19)16(15)13(18)8-7-11-5-3-2-4-6-11/h2-10,17,19H,1H3/b8-7+
|
||||
InChIKey |
NYSZJNUIVUBQMM-BQYQJAHWSA-N
|
||||
CAS Number |
CAS 19309-14-9
|
||||
Herb ID | |||||
ETMC ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | mTOR | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | S6K1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | XIAP | Molecule Info |
Pathway MAP
|
||
In-vitro Model | SK-OV-3 | CVCL_0532 | Ovarian serous cystadenocarcinoma | Homo sapiens | ||
A2780 | CVCL_0134 | Ovarian endometrioid adenocarcinoma | Homo sapiens | |||
Experimental
Result(s) |
Cardamonin enhances the anti-proliferative effect of cisplatin on ovarian cancer by suppressing the expression of anti-apoptotic proteins and activation of mTOR. | |||||
5-fluorouracil | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | ABCB1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | CTNNB1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | TCF7L2 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | BGC-823 | CVCL_3360 | Gastric cancer | Homo sapiens | ||
In-vivo Model | BGC-823/5-FU cells (5*106) were injected subcutaneously into the left flank of six-week-old BALB/c nude mice. | |||||
Experimental
Result(s) |
Cardamonin reduces 5-fluorouracil resistance of gastric cancer cells through targeting Wnt/beta-catenin signal pathway. | |||||
Doxorubicin | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [4] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | ALDH1A1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | CCL2 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | EZH2 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | IL6 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | MYC | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | NANOG | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | POU5F1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | SETDB1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | SMYD3 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | SOX2 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | STAT3 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | SUM190PT | CVCL_3423 | Breast inflammatory carcinoma | Homo sapiens | ||
MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | |||
CAMA-1 | CVCL_1115 | Breast adenocarcinoma | Homo sapiens | |||
In-vivo Model | To establish breast cancer xenografts in nude mice, SUM190 cells were mixed with Matrigel and injected under aseptic conditions into mammary fat pads of nude mice (n = 4-8 for each group, 2 * 106 cells per fat pad). | |||||
Experimental
Result(s) |
Cardamonin reduces chemotherapy-enriched breast cancer stem-like cells in vitro and in vivo. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Beta-catenin (CTNNB1) | Molecule Info | [5] | |
Caterpiller protein 1.1 (NLRP3) | Molecule Info | [6] | ||
DNA-binding factor KBF1 (p105) | Molecule Info | [5] | ||
Hypoxia-inducible factor 1 alpha (HIF-1A) | Molecule Info | [1] | ||
Interleukin-1 beta (IL1B) | Molecule Info | [6] | ||
Toll-like receptor 3 (TLR3) | Molecule Info | [5] | ||
KEGG Pathway | HIF-1 signaling pathway | Click to Show/Hide | ||
2 | mTOR signaling pathway | |||
3 | Thyroid hormone signaling pathway | |||
4 | Pathways in cancer | |||
5 | Proteoglycans in cancer | |||
6 | Renal cell carcinoma | |||
7 | Central carbon metabolism in cancer | |||
8 | Choline metabolism in cancer | |||
9 | Toll-like receptor signaling pathway | |||
10 | Hepatitis C | |||
11 | Hepatitis B | |||
12 | Influenza A | |||
13 | Herpes simplex infection | |||
14 | MAPK signaling pathway | |||
15 | Cytokine-cytokine receptor interaction | |||
16 | NF-kappa B signaling pathway | |||
17 | Apoptosis | |||
18 | Osteoclast differentiation | |||
19 | NOD-like receptor signaling pathway | |||
20 | Cytosolic DNA-sensing pathway | |||
21 | Hematopoietic cell lineage | |||
22 | TNF signaling pathway | |||
23 | Inflammatory mediator regulation of TRP channels | |||
24 | Non-alcoholic fatty liver disease (NAFLD) | |||
25 | Type I diabetes mellitus | |||
26 | Alzheimer's disease | |||
27 | Prion diseases | |||
28 | Salmonella infection | |||
29 | Pertussis | |||
30 | Legionellosis | |||
31 | Leishmaniasis | |||
32 | Chagas disease (American trypanosomiasis) | |||
33 | African trypanosomiasis | |||
34 | Malaria | |||
35 | Amoebiasis | |||
36 | Tuberculosis | |||
37 | Measles | |||
38 | Inflammatory bowel disease (IBD) | |||
39 | Rheumatoid arthritis | |||
40 | Graft-versus-host disease | |||
41 | Rap1 signaling pathway | |||
42 | Wnt signaling pathway | |||
43 | Hippo signaling pathway | |||
44 | Focal adhesion | |||
45 | Adherens junction | |||
46 | Tight junction | |||
47 | Signaling pathways regulating pluripotency of stem cells | |||
48 | Leukocyte transendothelial migration | |||
49 | Melanogenesis | |||
50 | Bacterial invasion of epithelial cells | |||
51 | Pathogenic Escherichia coli infection | |||
52 | HTLV-I infection | |||
53 | Colorectal cancer | |||
54 | Endometrial cancer | |||
55 | Prostate cancer | |||
56 | Thyroid cancer | |||
57 | Basal cell carcinoma | |||
58 | Arrhythmogenic right ventricular cardiomyopathy (ARVC) | |||
59 | Ras signaling pathway | |||
60 | cAMP signaling pathway | |||
61 | Chemokine signaling pathway | |||
62 | Sphingolipid signaling pathway | |||
63 | PI3K-Akt signaling pathway | |||
64 | RIG-I-like receptor signaling pathway | |||
65 | T cell receptor signaling pathway | |||
66 | B cell receptor signaling pathway | |||
67 | Neurotrophin signaling pathway | |||
68 | Prolactin signaling pathway | |||
69 | Adipocytokine signaling pathway | |||
70 | Cocaine addiction | |||
71 | Epithelial cell signaling in Helicobacter pylori infection | |||
72 | Shigellosis | |||
73 | Toxoplasmosis | |||
74 | Epstein-Barr virus infection | |||
75 | Transcriptional misregulation in cancer | |||
76 | Viral carcinogenesis | |||
77 | MicroRNAs in cancer | |||
78 | Pancreatic cancer | |||
79 | Chronic myeloid leukemia | |||
80 | Acute myeloid leukemia | |||
81 | Small cell lung cancer | |||
NetPath Pathway | IL5 Signaling Pathway | Click to Show/Hide | ||
2 | Notch Signaling Pathway | |||
3 | TCR Signaling Pathway | |||
4 | Leptin Signaling Pathway | |||
5 | IL1 Signaling Pathway | |||
6 | IL2 Signaling Pathway | |||
7 | IL3 Signaling Pathway | |||
8 | TGF_beta_Receptor Signaling Pathway | |||
9 | Wnt Signaling Pathway | |||
10 | TNFalpha Signaling Pathway | |||
Panther Pathway | Angiogenesis | Click to Show/Hide | ||
2 | Hypoxia response via HIF activation | |||
3 | VEGF signaling pathway | |||
4 | Toll receptor signaling pathway | |||
5 | Alzheimer disease-presenilin pathway | |||
6 | Cadherin signaling pathway | |||
7 | Wnt signaling pathway | |||
8 | p53 pathway feedback loops 2 | |||
9 | CCKR signaling map ST | |||
10 | Apoptosis signaling pathway | |||
11 | T cell activation | |||
Pathwhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | Click to Show/Hide | ||
2 | Intracellular Signalling Through Adenosine Receptor A2b and Adenosine | |||
Pathway Interaction Database | AP-1 transcription factor network | Click to Show/Hide | ||
2 | Hypoxic and oxygen homeostasis regulation of HIF-1-alpha | |||
3 | VEGFR1 specific signals | |||
4 | HIF-1-alpha transcription factor network | |||
5 | Notch-mediated HES/HEY network | |||
6 | Endogenous TLR signaling | |||
7 | IL27-mediated signaling events | |||
8 | IL12-mediated signaling events | |||
9 | IL1-mediated signaling events | |||
10 | IFN-gamma pathway | |||
11 | IL23-mediated signaling events | |||
12 | Cellular roles of Anthrax toxin | |||
13 | Degradation of beta catenin | |||
14 | Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) | |||
15 | Coregulation of Androgen receptor activity | |||
16 | Arf6 trafficking events | |||
17 | Presenilin action in Notch and Wnt signaling | |||
18 | Integrin-linked kinase signaling | |||
19 | Nectin adhesion pathway | |||
20 | CDC42 signaling events | |||
21 | Canonical Wnt signaling pathway | |||
22 | FoxO family signaling | |||
23 | E-cadherin signaling events | |||
24 | Posttranslational regulation of adherens junction stability and dissassembly | |||
25 | E-cadherin signaling in the nascent adherens junction | |||
26 | E-cadherin signaling in keratinocytes | |||
27 | Regulation of nuclear beta catenin signaling and target gene transcription | |||
28 | Stabilization and expansion of the E-cadherin adherens junction | |||
29 | Signaling events mediated by VEGFR1 and VEGFR2 | |||
30 | N-cadherin signaling events | |||
31 | RAC1 signaling pathway | |||
32 | TGF-beta receptor signaling | |||
33 | Fc-epsilon receptor I signaling in mast cells | |||
34 | BCR signaling pathway | |||
35 | LPA receptor mediated events | |||
36 | Atypical NF-kappaB pathway | |||
37 | Canonical NF-kappaB pathway | |||
38 | CD40/CD40L signaling | |||
39 | Alternative NF-kappaB pathway | |||
40 | Osteopontin-mediated events | |||
41 | Angiopoietin receptor Tie2-mediated signaling | |||
42 | Signaling events mediated by HDAC Class I | |||
43 | Regulation of Telomerase | |||
44 | Glucocorticoid receptor regulatory network | |||
45 | TNF receptor signaling pathway | |||
46 | IL2 signaling events mediated by PI3K | |||
47 | Ceramide signaling pathway | |||
48 | amb2 Integrin signaling | |||
49 | HIV-1 Nef: Negative effector of Fas and TNF-alpha | |||
50 | EPO signaling pathway | |||
Reactome | Regulation of gene expression by Hypoxia-inducible Factor | Click to Show/Hide | ||
2 | Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | |||
3 | BMAL1:CLOCK,NPAS2 activates circadian gene expression | |||
4 | NOTCH1 Intracellular Domain Regulates Transcription | |||
5 | Circadian Clock | |||
6 | Ligand-dependent caspase activation | |||
7 | MyD88-independent TLR3/TLR4 cascade | |||
8 | Trafficking and processing of endosomal TLR | |||
9 | RIP-mediated NFkB activation via ZBP1 | |||
10 | TRIF-mediated programmed cell death | |||
11 | Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon | |||
12 | IKK complex recruitment mediated by RIP1 | |||
13 | TRAF6 mediated induction of TAK1 complex | |||
14 | Interleukin-1 signaling | |||
15 | Interleukin-1 processing | |||
16 | CLEC7A/inflammasome pathway | |||
17 | TCF dependent signaling in response to WNT | |||
18 | Formation of the beta-catenin:TCF transactivating complex | |||
19 | LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | |||
20 | CDO in myogenesis | |||
21 | Deactivation of the beta-catenin transactivating complex | |||
22 | Ca2+ pathway | |||
23 | Binding of TCF/LEF:CTNNB1 to target gene promoters | |||
24 | Disassembly of the destruction complex and recruitment of AXIN to the membrane | |||
25 | S33 mutants of beta-catenin aren't phosphorylated | |||
26 | S37 mutants of beta-catenin aren't phosphorylated | |||
27 | S45 mutants of beta-catenin aren't phosphorylated | |||
28 | T41 mutants of beta-catenin aren't phosphorylated | |||
29 | RHO GTPases activate IQGAPs | |||
30 | Activation of NF-kappaB in B cells | |||
31 | Regulated proteolysis of p75NTR | |||
32 | NF-kB is activated and signals survival | |||
33 | Senescence-Associated Secretory Phenotype (SASP) | |||
34 | FCERI mediated NF-kB activation | |||
35 | DEx/H-box helicases activate type I IFN and inflammatory cytokines production | |||
36 | Transcriptional regulation of white adipocyte differentiation | |||
37 | TAK1 activates NFkB by phosphorylation and activation of IKKs complex | |||
38 | IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) | |||
39 | IkBA variant leads to EDA-ID | |||
40 | CLEC7A (Dectin-1) signaling | |||
41 | CD209 (DC-SIGN) signaling | |||
42 | MAP3K8 (TPL2)-dependent MAPK1/3 activation | |||
43 | TRAF6 mediated NF-kB activation | |||
WikiPathways | SIDS Susceptibility Pathways | Click to Show/Hide | ||
2 | Notch Signaling Pathway | |||
3 | Regulation of Hypoxia-inducible Factor (HIF) by Oxygen | |||
4 | Signaling by NOTCH1 | |||
5 | Oncostatin M Signaling Pathway | |||
6 | Adipogenesis | |||
7 | AGE/RAGE pathway | |||
8 | Circadian Clock | |||
9 | Angiogenesis | |||
10 | Toll-like receptor signaling pathway | |||
11 | Cytosolic sensors of pathogen-associated DNA | |||
12 | Toll-Like Receptors Cascades | |||
13 | MyD88-independent cascade | |||
14 | Trafficking and processing of endosomal TLR | |||
15 | Regulation of toll-like receptor signaling pathway | |||
16 | Monoamine Transport | |||
17 | TCR Signaling Pathway | |||
18 | Type II interferon signaling (IFNG) | |||
19 | Senescence and Autophagy in Cancer | |||
20 | Cytokines and Inflammatory Response | |||
21 | MAPK Signaling Pathway | |||
22 | Myometrial Relaxation and Contraction Pathways | |||
23 | Aryl Hydrocarbon Receptor Pathway | |||
24 | IL1 and megakaryotyces in obesity | |||
25 | Hematopoietic Stem Cell Differentiation | |||
26 | Spinal Cord Injury | |||
27 | Allograft Rejection | |||
28 | Alzheimers Disease | |||
29 | Leptin signaling pathway | |||
30 | IL-1 signaling pathway | |||
31 | Interleukin-1 signaling | |||
32 | Folate Metabolism | |||
33 | Vitamin B12 Metabolism | |||
34 | Selenium Micronutrient Network | |||
35 | Serotonin Transporter Activity | |||
36 | NOD pathway | |||
37 | DNA Damage Response (only ATM dependent) | |||
38 | TGF Beta Signaling Pathway | |||
39 | Wnt Signaling Pathway | |||
40 | Wnt Signaling Pathway and Pluripotency | |||
41 | Wnt Signaling Pathway Netpath | |||
42 | Focal Adhesion | |||
43 | Extracellular vesicle-mediated signaling in recipient cells | |||
44 | Ectoderm Differentiation | |||
45 | Endoderm Differentiation | |||
46 | Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | |||
47 | Hair Follicle Development: Organogenesis (Part 2 of 3) | |||
48 | Hair Follicle Development: Induction (Part 1 of 3) | |||
49 | Primary Focal Segmental Glomerulosclerosis FSGS | |||
50 | BDNF signaling pathway | |||
51 | Integrated Pancreatic Cancer Pathway | |||
52 | Gastric cancer network 2 | |||
53 | Corticotropin-releasing hormone | |||
54 | Pathogenic Escherichia coli infection | |||
55 | Arrhythmogenic Right Ventricular Cardiomyopathy | |||
56 | Neural Crest Differentiation | |||
57 | TWEAK Signaling Pathway | |||
58 | miR-targeted genes in muscle cell - TarBase | |||
59 | miR-targeted genes in lymphocytes - TarBase | |||
60 | miR-targeted genes in leukocytes - TarBase | |||
61 | Integrated Breast Cancer Pathway | |||
62 | Myogenesis | |||
63 | Heart Development | |||
64 | MicroRNAs in cardiomyocyte hypertrophy | |||
65 | Androgen receptor signaling pathway | |||
66 | Oxidative Stress | |||
67 | IL-4 Signaling Pathway | |||
68 | Apoptosis Modulation by HSP70 | |||
69 | Apoptosis-related network due to altered Notch3 in ovarian cancer | |||
70 | Selenium Metabolism and Selenoproteins | |||
71 | Cardiac Hypertrophic Response | |||
72 | Fc epsilon receptor (FCERI) signaling | |||
73 | Transcriptional Regulation of White Adipocyte Differentiation | |||
74 | Signaling by the B Cell Receptor (BCR) | |||
75 | TAK1 activates NFkB by phosphorylation and activation of IKKs complex | |||
76 | Structural Pathway of Interleukin 1 (IL-1) | |||
77 | EBV LMP1 signaling | |||
78 | Aryl Hydrocarbon Receptor | |||
79 | T-Cell Receptor and Co-stimulatory Signaling | |||
80 | Apoptosis | |||
81 | Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | |||
82 | TNF alpha Signaling Pathway | |||
83 | B Cell Receptor Signaling Pathway | |||
84 | TSLP Signaling Pathway | |||
85 | IL17 signaling pathway | |||
86 | RANKL/RANK Signaling Pathway | |||
87 | Signalling by NGF | |||
88 | TCR signaling | |||
89 | RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways | |||
90 | Interleukin-1 processing | |||
91 | Apoptosis Modulation and Signaling | |||
92 | TFs Regulate miRNAs related to cardiac hypertrophy | |||
93 | Osteopontin Signaling |